Free Trial

Brokerages Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) PT at $8.29

Ventyx Biosciences logo with Medical background

Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Get Free Report) have been given an average rating of "Moderate Buy" by the eight analysts that are presently covering the stock, MarketBeat.com reports. Four investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $8.29.

VTYX has been the subject of a number of research analyst reports. Canaccord Genuity Group reduced their price objective on shares of Ventyx Biosciences from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Monday, August 12th. Wells Fargo & Company dropped their target price on Ventyx Biosciences from $16.00 to $11.00 and set an "overweight" rating for the company in a report on Monday, August 12th. Finally, HC Wainwright reissued a "neutral" rating and set a $6.00 target price on shares of Ventyx Biosciences in a report on Tuesday, October 15th.

Get Our Latest Research Report on Ventyx Biosciences

Ventyx Biosciences Price Performance

VTYX stock traded up $0.13 during midday trading on Monday, reaching $2.31. 1,153,754 shares of the company were exchanged, compared to its average volume of 2,106,598. The business has a 50-day moving average price of $2.22 and a two-hundred day moving average price of $2.98. Ventyx Biosciences has a one year low of $1.79 and a one year high of $15.81. The firm has a market capitalization of $163.25 million, a price-to-earnings ratio of -0.83 and a beta of 0.36.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.45) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.12. As a group, analysts anticipate that Ventyx Biosciences will post -2.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of VTYX. Norden Group LLC acquired a new position in Ventyx Biosciences in the first quarter valued at about $59,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in Ventyx Biosciences during the first quarter worth about $72,000. First Light Asset Management LLC acquired a new position in Ventyx Biosciences during the first quarter worth about $3,437,000. Redmile Group LLC raised its stake in Ventyx Biosciences by 944.4% during the first quarter. Redmile Group LLC now owns 2,164,126 shares of the company's stock worth $11,903,000 after acquiring an additional 1,956,923 shares in the last quarter. Finally, Ikarian Capital LLC raised its stake in Ventyx Biosciences by 8,483.8% during the first quarter. Ikarian Capital LLC now owns 507,647 shares of the company's stock worth $2,792,000 after acquiring an additional 501,733 shares in the last quarter. Institutional investors and hedge funds own 97.88% of the company's stock.

Ventyx Biosciences Company Profile

(Get Free Report

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

See Also

Analyst Recommendations for Ventyx Biosciences (NASDAQ:VTYX)

Should you invest $1,000 in Ventyx Biosciences right now?

Before you consider Ventyx Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ventyx Biosciences wasn't on the list.

While Ventyx Biosciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Why Whitestone REIT is Outperforming in 2024: 35% Growth & Monthly Dividends
Why SoundHound Stock Dip Could Mean Big Gains for 2025 Investors
Nintendo Stock: Buy Before the 2025 Switch Platform Hits!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines